Together, these findings reinforce that both metformin pharmacokinetics (via SLC47A1) and pharmacodynamics (via CAPN10) are subject to genetic regulation, supporting genotype-guided therapy in metabolic disease. This evidence concerns the gene SLC47A1 and metabolic disease.